Ascendia Pharmaceuticals Participates in Virtual Nasdaq Opening Bell Ceremony Celebrating J.P. Morgan Healthcare Conference
Ascendia Pharmaceuticals participated in the virtual Nasdaq Opening Bell Ceremony on Monday, January 10, 2022 to celebrate the first day of the 40th Annual J.P. Morgan Healthcare Conference. The Ascendia team met with representatives of leading pharmaceutical and biopharma companies throughout the conference to discuss how its CDMO services can help them overcome the most difficult drug formulation challenges.
Healthcare companies within the Nasdaq Biotechnology Index (NBI), as well as select other healthcare companies – including Ascendia Pharmaceuticals – were featured in the virtual event. The Ceremony began at 9:00 a.m. EST when Ascendia’s logo, as well as those of other participating companies, were featured on Nasdaq’s 7-story tower in New York City’s Times Square. The Ceremony included Ascendia CEO Jim Huang being part of the CEO spotlight during the countdown to the Opening Bell at 9:29 a.m. EST.
A streaming video of the Ceremony highlights the virtual event. Ascendia appears at the 58:25 mark.
Delivering Sophisticated Formulations
Ascendia participated in Fierce JPM Week 2022 to meet with companies seeking CDMOs to help improve their drug development pipelines. The meetings highlighted how Ascendia partners with companies to provide custom sterile- and non-sterile-enabling formulations and manufacturing, as well as analytical methods for new chemical entities, complex dosage forms, and 505(B)(2) product development, as well as OTCs, nutraceuticals, and animal health.
Ascendia delivers sophisticated formulations to enhance bioavailability and solubility using three proprietary nanotechnologies – NanoSol®, EmulSol®, and AmorSol®. Ascendia’s facility in New Brunswick, NJ has Class 10,000 (ISO 7) and Class 100 (ISO 5) cleanrooms, as well as Class 10,000 (ISO 7) manufacturing suites. Ascendia manufactures cGMP batches for orally administered dosage forms. It also provides cGMP manufacture of sterile, injectable dosage forms.
To learn more about Ascendia’s services, contact our team.Back to articles
Want to learn more about
Get up-to-date informationStay in touch >